den patients in intensive care unit or after surgery intervention commonly develop skeletal muscle weakness. The latter is promoted by a variety of prolonged hospitalization-associated conditions. Muscle disuse is the most ubiquitous and contributes to rapid skeletal muscle atrophy and progressive functional strength reduction. Disuse causes a reduction in fatty acid oxidation, leading to its accumulation in skeletal muscle. We hypothesized that muscle fatty acid accumulation could stimulate ceramide synthesis and promote skeletal muscle weakness. Therefore, the present study was designed to determine the effects of sphingolipid metabolism on skeletal muscle atrophy induced by 7 days of disuse. For this purpose, male Wistar rats were treated with myriocin, an inhibitor of de novo synthesis of ceramides, and subjected to hindlimb unloading (HU) for 7 days. Soleus muscles were assayed for fiber diameter, ceramide levels, protein degradation, and apoptosis signaling. Serum and liver were removed to evaluate the potential hepatoxicity of myriocin treatment. We found that HU increases content of saturated C16:0 and C18:0 ceramides and decreases soleus muscle weight and fiber diameter. HU increased the level of polyubiquitinated proteins and induced apoptosis in skeletal muscle. Despite a prevention of C16:0 and C18:0 muscle accumulation, myriocin treatment did not prevent skeletal muscle atrophy and concomitant induction of apoptosis and proteolysis. Moreover, myriocin treatment increased serum transaminases and induced hepatocyte necrosis. These data highlight that inhibition of de novo synthesis of ceramides during immobilization is not an efficient strategy to prevent skeletal muscle atrophy and exerts adverse effects like hepatotoxicity.
ubiquitous cause and contributes to rapid skeletal muscle atrophy and reduction in muscle strength (14) .
Extensive research have been conducted to identify potential triggers and molecular signaling involved in skeletal muscle atrophy during disuse (13, 40, 42) . Studies using bed rest or hindlimb unloading (HU) models showed that muscle mass loss results from a decrease in protein synthesis combined with an increase in proteolysis rate and apoptosis (27) . The downregulation of Akt/mammalian target of rapamycin (mTOR) anabolic signaling pathway mainly contributes to the decrease in protein synthesis rate, whereas muscle protein degradation is primary regulated via the ubiquitin-proteasome pathway including the ubiquitin ligase muscle RING finger 1 (MuRF1) and muscle atrogin1/muscle atrophy F-box (MAFbx). The apoptosis-related endoproteases (i.e., caspases) also play a key role in muscle atrophy by both degrading myofibrillar proteins and inducing myonuclear apoptosis (50) .
Ceramides are bioactive lipids involved in cell responses to stress by acting as a second messenger in the sphingomyelin signaling pathway (48) . They are synthesized through both stimulation of sphingomyelinase-mediated hydrolysis of membrane sphingomyelin and de novo synthesis involving a condensation of palmitoyl-CoA with serine (22) . Relationships between ceramides and the pathogenesis of insulin resistance have been extensively studied during the last decade (48) . More recently, in vitro studies also highlighted a potential role of these ectopic lipids in skeletal muscle atrophy (11, 35, 54) . In cultured myotubes, ceramides are indeed recognized to inhibit myogenic differentiation (35) and protein synthesis (26) but also to stimulate muscle proteolysis and apoptosis through the activation of NF-B and caspase signaling pathways (11, 37, 54) .
Recent advances have linked changes in muscle sphingolipid metabolism and development of cancer cachexia and sarcopenia. Specifically, it has been demonstrated that aging increased ceramide content in human and rodent skeletal muscle (41) . These elevations seem to play a key role in the aging-related reduction in muscle protein synthesis and consequently in sarcopenia development (41, 51) . On the other hand, De Larichaudy and colleagues (11) have demonstrated that inhibition of de novo ceramide synthesis efficiently prevented muscle atrophy in a mice model of cancer-induced cachexia. Whereas accumulation of intramuscular lipids has been reported in bedridden patients (4, 10) , the effects of disuse on muscle ceramide synthesis are surprisingly unknown. However, the understanding of the role of sphingolipid metabolism could provide critical information to help with the identifica-tion of new molecular targets to prevent skeletal muscle atrophy in bedridden patients.
From these data, we hypothesized that inhibition of de novo synthesis of ceramides would prevent disuse-induced muscle proteolysis and apoptosis and consequently skeletal muscle atrophy. Therefore, the present study was designed to analyze in rats whether modulation of sphingolipid metabolism during disuse affects the development of skeletal muscle atrophy. For this purpose, we used a short-term HU rat model, treated or not animals with myriocin, an inhibitor of de novo synthesis of ceramides (7).
MATERIALS AND METHODS
All procedures described below were approved by the French Ministry of Higher Education and Research in accordance with the local committee on Ethics in Research of Rennes (veterinary service of health and animal protection, authorization 01259.03).
Animal care and protocol. Thirty-two young male Wistar rats (ϳ300 g) were housed in a temperature-controlled room (21 Ϯ 2°C) with a 12-h:12-h light/dark cycle and received standard rodent chow and water ad libitum. After 1 wk of acclimatization, these animals were assigned into four experimental groups: weight-bearing group (Control) (n ϭ 8), weight-bearing group treated with myriocin (Control-Myr) (n ϭ 8), HU group (HU) (n ϭ 8), or HU group treated with myriocin (HU-Myr) (n ϭ 8). After 7 days, rats were anesthetized with a ketamine-xylazine-butorphanol cocktail. Soleus muscle, liver, and spleen were weighed and immediately frozen in liquid nitrogen or fixed in 4%-paraformaldehyde (PFA). Venous blood was collected into dry tubes and centrifuged (1,500 g, 10 min) for serum sampling.
Hindlimb suspension and myriocin treatment. HU was performed using Morey's tail-suspension model (12, 38) . Briefly, Elastoplast tape was wrapped along the long axis of each animal's tail. A metal clip on the tape was attached to a nylon monofilament line via a stainless steel swivel. The distal end of the nylon line was attached to an overhead support and was shortened to suspend the animal in a 30°h ead-down tilt position. The swivel enabled the animal to explore the cage (360°range of motion) and obtain food and water freely. Animals were observed daily for changes in appearance and activity. To inhibit muscle serine palmitoyl transferase activity, we treated rats with a daily dose of myriocin (0.3 kg/mg ip) as previously described (7, 30) . Control rats received saline vehicle according to the same schedule.
Histology and immunochemistry analyses. Soleus muscle and liver samples were PFA fixed and paraffin embedded in blocks for 24 h. Serial transverse sections of 4 m were obtained from each sample using a LEICA microtome and were mounted on glass slides, three cuts in each. Liver sections were stained with hematoxylin and eosin saffron and Sirius red. The muscle cuts were performed in the wider part of the soleus muscle. Subsequently, the muscle sections were stained using the Gomori method for the reticulin stain. All the histological sections were scanned (ϫ20 objective) to measure the minimal Feret's diameter of muscle fiber using the Image J software (NIH, Bethesda, MD). Mean fiber diameter for each muscle was determined from at least 200 fibers per muscle.
To determine apoptotic cell death, cleaved caspase-3 staining was performed using a rabbit anti-cleaved caspase-3 antibody (1:500; Cell Signaling, Beverly, MA). Alkaline phosphatase was used as chromogen. Sections were scanned using a ϫ20 lens and analyzed using the Image J software (NIH). Cleaved caspase-3-positive cells were counted within the muscle tissue (Ϸ10-15 fields/muscle), and data were given as positive nuclei cells per square millimeter.
Serum analyses. Alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP) activities were performed in serum using Automated Beckman Coulter (Beckman Coulter, Brea, CA). Serum glucose, cholesterol, and triglycerides (TG) were measured using the same apparatus.
Quantification of sphingolipids and ceramides. Sphingolipids were extracted from ϳ40 mg of homogenized muscle using acidified cyclohexane/isopropanol mixture (60:40, vol/vol, 0.1% formic acid) and purified on NH 2 SPE cartridges (silica gel cartridges, 100 mg) to obtain distinct fractions of ceramides and sphingomyelins (5). The sphingolipid fractions were then quantified by UHPLC-ESI-MS/MS using an Acquity H-Class UHPLC system (Waters, Milford, MA) combined with a Waters Xevo TQD triple quadripole mass spectrometer. Lipid extracts were injected onto a C18 BEH column (2.1 mm ϫ 50.0 mm, 1.7-m particles; Waters) held to 43°C to separate all species of ceramides and sphingomyelins with two different LC elution gradients. For ceramide species separation, the gradient started at 95% of eluent B (mobile phase of water and of methanol with 1% formic acid and 5 mM ammonium formate), up to 98% in 4 min, then rapidly decreased to 95% for 0.1 min, and was maintained for 2 min. For sphingomyelin species separation, the gradient started at 95% of eluent B, up to 99% for 6 min, then rapidly decreased to 95% for 0.1 min, and was maintained for 1.4 min. Multiple reaction-monitoring mode in positive electrospray ionization was used to quantify each species of ceramides and sphingomyelins. The source heater temperature hold at 150°C, and the capillary voltage was set at 3.2 kV. The flow rate of desolvation gas was of 650 l/h at 350°C, and the cone voltage varied from 26 -58 V. Argon was used as the collision gas, and collision energies varied from 12-40 eV. Data analyses were performed by Mass Lynx software version 4.1 (Waters, Manchester, UK). Sphingolipid quantification was possible with calibration curves constructed by plotting the peak area ratios of analyses to the respective internal standard against concentration using a linear regression model. The quantification measurements were performed using the TargetLinks software (Waters).
Cytosolic protein extraction for immunoblot analyses. Cytosolic protein extraction was performed from soleus in cold lysis buffer containing 10.0 mM Tris·HCl, pH 7.4, 0.5 M sucrose, 50.0 mM NaCl, 5.0 mM EDTA, 30.0 mM Na4P2O7, 1% NP-40, 0.25% sodium deoxycholate, 50.0 mM NaF, 100.0 M sodium orthovanadate, and protease inhibitor cocktail (5 l/ml, P8340; Sigma, St. Louis, MO). The samples were homogenized using a Polytron homogenizer at 4°C. Each sample was then incubated on ice for 30 min followed by 3 ϫ 10 s of sonication. The homogenates were transferred to microcentrifuge tubes and centrifuged at 12,000 g for 12 min at 4°C. The protein concentration of the supernatant was determined by a Lowry assay using bovine serum albumin as a standard. Samples were then diluted in SDS-PAGE sample buffer (50 mM Tris·HCl, pH 6.8, 2% SDS, 10% glycerol, 5% ␤-mercaptoethanol, and 0.1% bromophenol blue) and heated 5 min at 95°C until analyses.
Western immunoblot analyses. Samples containing 60 g of proteins were resolved on 12.5% SDS-PAGE. The proteins were transferred at 240 mA for 90 min onto a 0.2-m nitrocellulose membrane. Membranes were blocked with 5% BSA or nonfat dry milk in Tris-buffered saline/0.05% Tween-20 (TBST) for 1 h at room temperature. Membranes were incubated overnight at 4°C with appropriate primary antibodies: Akt (1:1,000, Cell Signaling), Akt phosphoSer 473 (1:1,000, Cell Signaling), I-B␣ (1:1,000, Cell Signaling), p65 Ser 536 (1:1,000, Cell Signaling), p65 (1:1,000, Cell Signaling), MuRF1 (1:2,000; Abcam, Cambridge, MA), ubiquitin (1:1,000, Cell Signaling), Bax (1:1,000, Cell Signaling), Bcl2 (1:1,000, Cell Signaling), and ␣-actin (1:700, Sigma Aldrich). Thereafter, membranes were washed with TBST and incubated for 1 h at room temperature with infrared dye-conjugated secondary antibodies (LI-COR, Lincoln, NE). After being washed, blots were captured using the Odyssey Imaging System (LI-COR). All blots were scanned, and densitometric analysis of the bands was conducted using GS-800 imaging densitometer and QuantityOne software. Phospho-specific signal was normalized to the total signal to estimate the ratio of activated marker.
Statistical analysis. Data are presented as means Ϯ SE. Significance of intergroup differences was examined using two-way ANOVA for muscle and serum comparisons. Normality and equal variance were checked before the statistical analysis was conducted. Significant main effects or interactions were further analyzed by the Tukey's post hoc test. If normality of the data was not present, the data were analyzed using an ANOVA on ranks and further analyzed by the Dunn's test. Statistical analysis was performed using Sigma Stat 3.11. For all statistical analyses, the level of significance was set at P Ͻ 0.05.
RESULTS
Myriocin does not prevent disuse-induced skeletal muscle atrophy. Body weight (BW) and muscle weight (MW):BW ratio (MW/BW) after 7 days of HU combined or not with myriocin treatment are shown in Fig. 1 . Whereas no significant differences were observed between groups at the beginning of experiments, BW was significantly lower in HU animals compared with weight-bearing animals after 7 days of unloading (P ϭ 0.005 for untreated animals, P ϭ 0.003 for myriocintreated animals, Fig. 1A ). More precisely, HU rats did not gain weight during 7 days of unloading contrary to weight-bearing rats (Ϫ1.0% vs. ϩ 9.7% BW variations compared with initial situation, respectively). Independently from HU, we found that myriocin-treated animals exhibited lower BW after 7 days compared with untreated animals (P ϭ 0.025 for weightbearing animals, P ϭ 0.003 for HU animals, Fig. 1A) .
Soleus MW and mean fiber diameter were used to evaluate the effects of HU and myriocin treatment on skeletal muscle atrophy. Values of both absolute and those normalized to BW of soleus weight are respectively 35% and 28% smaller in HU compared with weight-bearing rats (P Ͻ 0.001 for both parameters). In addition, mean fiber diameter of HU animals was decreased compared with weight-bearing animals (P Ͻ 0.001, Fig. 1, C and D) . Taken together, these data confirm that 7 days of HU induce skeletal muscle atrophy.
Myriocin treatment did not affect absolute values of soleus weight in both weight-bearing and HU animals but significantly increased MW/BW ratio in both weight-bearing rats (P Ͻ 0.001) and HU rats (P ϭ 0.021, Fig. 1B) . Moreover, no differences were found in mean fiber diameter between weightbearing treated and untreated animals, and between HU treated and untreated animals (Fig. 1C) . Together, all these data demonstrate that myriocin treatment failed to prevent skeletal muscle atrophy induced by 7 days of HU.
Both HU and myriocin affect glucose and lipid metabolism. The effects of HU and myriocin on serum metabolic parameters figure in Table 1 . We observed that HU induced a sixfold reduction in serum triglyceride concentrations (P Ͻ 0.05), whereas serum total cholesterol and glucose concentrations remained unchanged after 7 days of unloading. Myriocin treatment caused a significant decrease in serum triglycerides (Ϫ57%, P ϭ 0.04) and glucose concentrations (Ϫ43%, P Ͻ 0.001) in weight-bearing animals. Moreover, serum total cholesterol significantly increased in both weight-bearing and HU animals treated with myriocin compared with their untreated counterparts (ϩ127% and ϩ167%, respectively, P Ͻ 0.05). All these results showed that HU and disruption of de novo ceramide synthesis differentially affected systemic lipid and glucose metabolism.
Myriocin efficiently prevents muscle-saturated ceramide accumulation attributable to HU. Figure 2 presents the effects of HU and myriocin treatment on muscle sphingolipid metabolism. We found that total muscle ceramide content did not differ significantly between weight-bearing and HU animals (P ϭ 0.13, Fig. 2A ). Whereas unsaturated ceramide content is not affected by HU, saturated ceramide content tends to be higher in unloaded animals (ϩ11%, P ϭ 0.08, Fig. 2A ). Ceramides have fatty acid chain lengths that vary from 2 to 28 carbon atoms, and the most abundant in skeletal muscle are C16:0 and C18:0 moieties (15, 23) . Here, we presented six ceramide species with fatty acid residues ranging from C16:0 to C24:1. Individual moiety analyses (Fig. 2B) revealed that saturated ceramide accumulation was mainly due to increases in C16:0 (ϩ20%, P ϭ 0.026) and C18:0 (ϩ30%, P ϭ 0.002).
As expected, we observed that both weight-bearing and HU myriocin-treated animals presented lower total and saturated muscle ceramide content compared with their untreated counterparts ( Fig. 2A) . Moreover, we observed that myriocin treatment significantly prevented HU-associated accumulation of C16:0 (Ϫ15%, P ϭ 0.028, Fig. 2B ) and C18:0 moieties (P ϭ 0.043, Fig. 2B ). Among the multiple existing metabolic pathways, ceramide can be generated from hydrolysis of sphingomyelin through the action of either acid or neutral serum transaminases (34) . Consequently, we also evaluated the effects of HU and myriocin on muscle sphingomyelin content. Contrary to muscle ceramide content, we observed that HU did not affect total, saturated, unsaturated, and individual moieties of sphingomyelin (data not shown). Myriocin-treated animals exhibited lower total sphingomyelin content compared with untreated animals (Ϫ22%, P ϭ 0.004) because of lower content in both saturated (Ϫ21%, P ϭ 0.002) and unsaturated sphingomyelin (Ϫ29%, P ϭ 0.05).
Muscle protein degradation and apoptosis are upregulated after 7 days of HU but not prevented by myriocin treatment.
Loss of muscle mass during disuse is caused by several cellular mechanisms, including autophagy (6), myonuclei apoptosis (39) , and imbalance between protein synthesis and degradation (56) . Figure 3 shows representative Western blot and relative content of phosphorylated/whole expression level of key components involved in muscle protein degradation pathways. Seven days of HU increased muscle protein ubiquitination (ϩ91% vs. weight-bearing animals, P Ͻ 0.001, Fig. 3 , E and F). This increase was associated with an upregulation of the ubiquitin ligase MuRF1 protein expression in HU animals (ϩ73%, P ϭ 0.007, Fig. 3, C and F) . Whereas phosphorylation of p65 (Ser 536 ) was not affected by HU (Fig. 3, B and F) , I-B␣ protein content was significantly reduced after 7 days of HU (Ϫ28%, P ϭ 0.039, Fig. 3, A and F) . Moreover, phosphorylation of Akt (Ser 473 ) was lower in skeletal muscle of HU compared with weight-bearing rats (Ϫ57%, P ϭ 0.009, Fig. 3,  D and F) . Myriocin treatment failed to reduce such increases in HU animals (Fig. 3) . Surprisingly, weight-bearing animals treated with myriocin exhibited significant increases in protein ubiquitination (ϩ58%, P Ͻ 0.001) and MuRF1 protein expression (ϩ48%, P ϭ 0.045). Figure 4 presents the effects of HU and myriocin treatment on muscle apoptosis markers. Caspase-3 is a key inducer of apoptosis, which is activated by a proteolytic processing of its inactive zymogen into activated p17 and p12 fragments. Here, we observed that HU induced a threefold increase in the number of cleaved caspase-3-positive nuclei cells in untreated animals (P Ͻ 0.05, Fig. 4, A and B) . At the same time, we found that the proapoptotic factor Bax was significantly higher in HU compared with weight-bearing animals (ϩ46%, P ϭ 0.012, Fig. 4, C and E) , whereas the antiapoptotic factor Bcl2 was significantly reduced in these same animals (Ϫ43%, P ϭ 0.023, Fig. 4, D and E) . Myriocin treatment did not affect the number of cleaved caspase-3-positive nuclei cells and the variation of Bax and Bcl2 induced by HU (Fig. 4) .
Myriocin treatment induces liver toxicity.
We were systematically investigating whether 7 days of myriocin treatment may have significant effects on hepatic toxicity. Thus we found both in weight-bearing and HU animals that myriocin induced hepatitis, as demonstrated by the three-to sixfold increases in AST, ALT, and ALP activities in serum ( Table  2) . In addition histological studies demonstrated the presence of hepatocyte necrosis, associated with intralobular inflammation and presence of mitotic figures in hepatocytes (Fig. 5) . It is noteworthy that this acute hepatitis was associated to a significant lowering of LW/BW ratio in weight-bearing animals (Ϫ28% vs. untreated animals, P Ͻ 0.001) and HU animals (Ϫ17%, vs. untreated animals, P ϭ 0.003).
DISCUSSION
Among potential triggers and signaling pathways underlying muscle atrophy during disuse, ceramides might contribute to muscle wasting by activating proteolysis and apoptosis. Our data show that short-term unloading promotes muscle-saturated ceramide accumulation and that myriocin treatment fails to prevent disuse-induced muscle atrophy related to activation of proteolytic or apoptotic pathways. These observations highlight that ceramides are not necessary for short-term disuseinduced skeletal muscle atrophy. Bed rest and HU are associated, not only with a loss of skeletal muscle mass, but also with a shift in muscle fuel metabolism in favor of carbohydrate oxidation to lipid oxidation (2). In turn, this leads to an accumulation of nonoxidized fatty acids in skeletal muscle that is likely synthesized as intramuscular lipids (4, 10) . In the present study, we hypothesized that such increases in intramuscular lipid triglycerides during HU could stimulate ceramide synthesis, leading to their accumulation in skeletal muscle. Here, we reported significant differences in the content of specific ceramide carbon chains between weight-bearing and HU groups, both palmitic (C16:0) and stearic (C18:0) ceramides being significantly higher in HU animals. Interestingly, Rivas and colleagues (41) recently observed that aging also increases saturated ceramide content in human skeletal muscle, and, similarly to the present study, they reported an increase in palmitic, stearic, and arachidonic ceramide concentrations. A higher saturated ceramide species in HU animals appears consistent because saturated fatty acid oxidation decreased during muscle disuse, whereas muscle monounsaturated fatty acid oxidation is not affected (3, 4) . Muscle accumulation of C16:0 and C18:0 moieties during disuse are efficiently prevented with myriocin treatment, thus confirming the impact of myriocin on muscle sphingolipid metabolism. Ceramides are synthesized through the de novo synthesis pathway consisting of the condensation of palmitoylCoA with serine but also by stimulation of sphingomyelinasemediated hydrolysis of membrane sphingomyelin (22) . In the present study, both saturated and unsaturated sphingomyelin content remained unchanged in skeletal muscle, suggesting that muscle ceramide accumulation mainly results from de novo synthesis pathway during HU. Converse to our hypothesis, we did not observe any preventive effects of myriocin treatment on skeletal MW and muscle fiber diameter (Fig. 1) , demonstrating that increases in saturated ceramides in skeletal muscle during disuse do not play a key role in skeletal muscle atrophy.
Ceramides are well recognized as key players in the induction of cell signaling pathways involved in skeletal muscle proteolysis and autophagy (21, 37) . Among them, NF-B directly regulates the transcription of multiple genes involved in protein ubiquitination, such as the E3 ubiquitin ligases, MuRF1, and atrogin-1 (20, 58) . In agreement with previous studies (12, 58) , we showed that HU increased both protein ubiquitination and MuRF1 protein content in skeletal muscle (Fig. 3) . NF-B transcription activity is regulated through its release from I-B␣ for p65-p50 heterodimer in the cytoplasm (i.e., canonical pathway) or Bcl3 binding to p50 -p50 homodimer (i.e., alternative pathway) (25) . Interestingly, it is well known that I-B␣ degradation is required for the unloading-induced increase in protein ubiquitination and activation of alternative NF-B signaling pathway through Bcl3 overexpression (28) . In the present study, we observed that 7 days of HU decreased muscle I-B␣ protein content, which helps explain increases of MuRF1 expression and protein ubiquitination in unloaded animals (Fig. 3) . We hypothesized in the present study that myriocin treatment could reduce ceramide accumulation in skeletal muscle and prevent disuse-induced NF-B signaling pathway. Despite a slight tendency to prevent I-B␣ degradation and MuRF1 increase (P ϭ 0.15 and P ϭ 0.14 between HU and HU-Myr, respectively), myriocin treatment did not prevent an increase in protein ubiquitination (Fig. 3) . All together, these results demonstrated that ceramide does not play a major role in the activation of NF-B signaling pathway during disuse compared with other upstream activators yet identified, for example, reactive oxygen species (16) or AMPK (19) .
Akt is another key regulator of both proteolysis and protein synthesis in skeletal muscle by modulating FOXO and mTOR signaling pathways (42) . Recent studies have demonstrated that ceramide inhibited insulin-stimulated Akt phosphorylation in skeletal muscle cells (24, 33) . In agreement with previous studies (18, 47) , we observed that Akt phosphorylation is considerably reduced in skeletal muscle after 7 days of HU (Fig. 3) . Such reduction may contribute to dephosphorylation of the transcription factors FOXO, subsequent nuclear translocation, and atrogin-1 transcription previously observed with HU (31, 43) . Similar to NF-B signaling pathway, myriocin treatment did not modulate Akt phosphorylation during HU, demonstrating that ceramide does not modulate Akt signaling pathway during disuse.
Consistent data indicate that apoptosis is rapidly induced in skeletal muscle during disuse (44) . In the present study, we found that HU induced a threefold increase of the number of cleaved caspase-3-positive cells in skeletal muscle. This result is in accordance with previous studies observing an increase in apoptosis after 7 and 14 days of muscle unloading using TUNEL method or measuring caspase-3 activity (1, 17, 46) . DNA fragmentation through caspase-dependent pathway oc- curs through extrinsic (receptor) pathway or by intrinsic pathway via endoplasmic reticulum or mitochondria. Among all proteins involved in these processes, the proapoptotic and the antiapoptotic proteins Bax and Bcl2 are key regulators of the intrinsic mitochondrial apoptotic pathway by modulating the mitochondrial permeability and the release of proapoptotic proteins such as cytochrome c into the cytosol. Here, an increase of Bax and a reduction of Bcl2 protein content occurred in skeletal muscle after 7 days of unloading, attesting of an activation of the intrinsic mitochondrial pathway reported in previous studies (45) . Several studies have highlighted the role of ceramides in muscle apoptosis induction when saturated fatty acids accumulate in skeletal or cardiac muscle cells (49, 54) . Consequently, we hypothesized that preventing disuseinduced ceramide accumulation in skeletal muscle would reduce muscle apoptosis. Similar to previous cell signaling pathways, we did not observe a preventive effect of myriocin on Bax and Bcl2 protein expression, as well as in the number of cleaved caspase-3-positive cells in skeletal muscle. All together, these results suggest that muscle apoptosis observed during a short period of disuse is probably not regulated by de novo ceramide synthesis.
One important finding was the strong acute hepatotoxic impact induced by myriocin and demonstrated by both biochemical tests and histological analyses. Moreover, we found mitotic figures in hepatocytes suggesting that regeneration of hepatocytes was engaged to compensate for hepatocyte necrosis, which was likely responsible for the LW/BW ratio decrease. To our knowledge, such findings have never been reported in previous studies in rodents using the same dose and administration mode in animals. In mice, myriocin, 0.5 mg/kg injected intraperitoneally, has been reported to decrease viral C replication and has been evoked as a potential therapeutic issue during chronic viral hepatitis (52, 55) . In rat, myriocin has been reported to exert a protective effect on hepatic lipid deposition during nonalcoholic or alcoholic liver disease using the same daily doses of 0.3 mg/kg (30, 53) . However, none of these studies directly measured indicators of liver toxicity. Moreover, it must be underlined that FTY720, a synthetic compound based on the fungal secondary metabolite myriocin and potentially useful in multiple sclerosis, is also recognized in humans to exert side effects, including an increase of serum transaminases and hepatotoxity (29, 36) . Interestingly, Weber and colleagues (57) showed 20 years ago that liver injury contributed to increased muscle proteolysis, especially in glycolytic muscle fibers. Consequently, we cannot exclude that hepatic toxicity of myriocin observed in our experiments may have a biological impact on muscle structure, as suggested by the increase in MuRF1 and polyubiquinated protein content in skeletal muscle of weight-bearing rats. In any case, the potential hepatotoxic effect of myriocin should be considered in experimental models.
In summary, this study demonstrated that short-term disuse induces saturated ceramide accumulation in skeletal muscle, but this accumulation is not involved in skeletal muscle atrophy. Conversely to cancer cachexia, our results suggest that inhibition of ceramide synthesis with de novo synthesis inhibitors (e.g., myriocin or FTY720) should not be a promising strategy to limit muscle weakness associated with short periods of muscle disuse attributable to sickness or injury. Finally, our study indicates that one needs to be very cautious regarding the use of myriocin to investigate the relationships between ceramide and systemic biology in animal models because of its potential hepatotoxicity.
